logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
Showing 1 - 11 of 11 Items
Showing 1 - 11 of 11 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Concordance of three approaches for operationalizing outcome definitions for multidrug-resistant TB

Zeng C, Mitnick CD, Hewison CCH, Bastard M, Khan PY,  et al.
2023-01-01 • International Journal of Tuberculosis and Lung Disease
2023-01-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND
The WHO provides standardized outcome definitions for rifampicin-resistant (RR) and multidrug-resistant (MDR) TB. However, operationalizing these definitions can be challe...
Journal Article
|
Short Report

Culture conversion at six months in patients receiving delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis

Seung KJ, Khan PY, Franke MF, Ahmed SM, Aiylchiev S,  et al.
2019-11-02 • Clinical Infectious Diseases
2019-11-02 • Clinical Infectious Diseases
Delamanid should be effective against highly resistant strains of Mycobacterium tuberculosis, but uptake has been slow globally. In the endTB (expand new drug markets for TB) Observation...
Journal Article
|
Research

"My favourite day is Sunday": community perceptions of (drug-resistant) tuberculosis and ambulatory tuberculosis care in Kara Suu District, Osh Province, Kyrgyzstan

Burtscher D, Van der Bergh R, Toktosunov U, Angmo N, Samieva N,  et al.
2016-03-28 • PLOS One
2016-03-28 • PLOS One
Kyrgyzstan is one of the 27 high multidrug-resistant tuberculosis (MDR-TB) burden countries listed by the WHO. In 2012, Médecins Sans Frontières (MSF) started a drug-resistant tuberculos...
Journal Article
|
Research

Outcomes of HIV-infected versus HIV-non-infected patients treated for drug-resistance tuberculosis: Multicenter cohort study

Bastard M, Sanchez-Padilla E, du Cros PAK, Khamraev AK, Parpieva N,  et al.
2018-03-08 • PLOS One
2018-03-08 • PLOS One
The emergence of resistance to anti-tuberculosis (DR-TB) drugs and the HIV epidemic represent a serious threat for reducing the global burden of TB. Although data on HIV-negative DR-TB t...
Protocol
|
Research Protocol

The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens

Khan UT, Huerga H, Khan AS, Mitnick CD, Hewison CCH,  et al.
2019-08-20 • BMC Infectious Diseases
2019-08-20 • BMC Infectious Diseases
BACKGROUND
At a time when programs were struggling to design effective regimens for the treatment of multidrug-resistant tuberculosis (MDR-TB), the marketing authorization of bedaqui...
Journal Article
|
Research

Tuberculosis among migrants in Bishkek, the capital of the Kyrgyz Republic

Goncharova O, Denisiuk O, Zachariah R, Davtyan K, Nabirova D,  et al.
2017-09-01 • Public Health Action
2017-09-01 • Public Health Action
Setting: Twenty-two first-line, two second-line and one tertiary health facility in Bishkek, the capital of Kyrgyzstan. Objectives: Among migrants, a marginalised population at risk for ...
Journal Article
|
Research

Detecting tuberculosis: rapid tools but slow progress

England K, Masini T, Fajardo E
2019-09-21 • Public Health Action
2019-09-21 • Public Health Action
The World Health Organization (WHO) currently recommends Xpert® MTB/RIF as the initial test for all people with presumptive tuberculosis (TB). A number of challenges have been reported, ...
Journal Article
|
Research

What is the best culture conversion prognostic marker for patients treated for multidrug-resistant tuberculosis?

Bastard M, Sanchez-Padilla E, Hayrapetyan A, Kimenye K, Khurkhumal S,  et al.
2019-10-01 • International Journal of Tuberculosis and Lung Disease
2019-10-01 • International Journal of Tuberculosis and Lung Disease
INTRODUCTION
Identification of good prognostic marker for tuberculosis (TB) treatment response is a necessary step on the path towards a surrogate marker to reduce TB trial duration....
Conference Material
|
Poster

Kadamjay Area Biomonitoring (KAB) study, Kadamjay, Kyrgyzstan. A cross-sectional study

Aiylchiev S, Sharshenova A, Nascarella M, Sulaimanov E, Inagbe D,  et al.
2022-05-09 • MSF Scientific Days International 2022
2022-05-09 • MSF Scientific Days International 2022
Journal Article
|
Commentary

Public health advocacy for the Berlin Declaration on tuberculosis in the former Soviet Union: the view of Médecins Sans Frontières

Healy S, Dietrich S, Roth T, Nyang'wa BT, du Cros PAK
2012-12-11 • European Journal of Microbiology and Immunology
2012-12-11 • European Journal of Microbiology and Immunology
Journal Article
|
Research

Linkage Between Diagnosis and Treatment of Smear-Positive Pulmonary Tuberculosis in Urban and Rural Areas in Kyrgyzstan

Kulzhabaeva A, Nabirova D, Usenbaev N, Denisiuk O, Zachariah R
2016-03-01 • Public Health Panorama
2016-03-01 • Public Health Panorama
The performance of the tuberculosis (TB) programme should be judged on the basis of detected TB cases recorded in the laboratory register and not just those placed on treatment and recor...